Market Overview

UPDATE: Credit Suisse Upgrades Marsh & McLennan Companies on New Valuation Framework

Share:
Related MMC
Earnings Scheduled For July 28, 2016
BMO's Adjustment In Coverage Of AIG, Chubb Limited And The Insurance Sector

In a report published Wednesday, Credit Suisse analyst Michael Zaremski upgraded the rating on Marsh & McLennan Companies (NYSE: MMC) from Neutral to Outperform, and raised the price target from $45.00 to $48.00.

In the report, Credit Suisse noted, “We are upgrading shares of Marsh & McLennan to Outperform (target price increased to $48 from $45) in conjunction with our initiation of competitor consultant company Towers Watson (Neutral-rated). MMC's upgrade to Outperform centers around our analysis detailing (1) the earnings accretion opportunity afforded to healthcare consultants such as MMC as a result of healthcare exchange adoption and (2) our updated free cash flow based valuation framework which we believe is more reflective of earnings available to shareholders versus GAAP reported EPS.”

Marsh & McLennan Companies closed on Tuesday at $43.85.

Latest Ratings for MMC

DateFirmActionFromTo
Jul 2016Keefe Bruyette & WoodsMaintainsOutperform
Jul 2016Deutsche BankMaintainsBuy
Apr 2016CitigroupMaintainsBuy

View More Analyst Ratings for MMC
View the Latest Analyst Ratings

Posted-In: Credit Suisse Michael ZaremskiAnalyst Color Upgrades Analyst Ratings

 

Related Articles (MMC)

View Comments and Join the Discussion!